These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18297438)

  • 21. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral treatment for cirrhosis due to hepatitis C: a review.
    Somasundaram A; Venkataraman J
    Singapore Med J; 2012 Apr; 53(4):231-5. PubMed ID: 22511042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
    Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
    Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
    Gramenzi A; Andreone P; Fiorino S; Cammà C; Giunta M; Magalotti D; Cursaro C; Calabrese C; Arienti V; Rossi C; Di Febo G; Zoli M; Craxì A; Gasbarrini G; Bernardi M
    Gut; 2001 Jun; 48(6):843-8. PubMed ID: 11358906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis.
    Yoshida T; Muto Y; Moriwaki H; Yamato M
    Gastroenterol Jpn; 1989 Dec; 24(6):692-8. PubMed ID: 2606303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Additional BCAA-enriched nutrient mixture improves the nutritional condition in cirrhotic patients with hypoalbuminemia despite treatment with regular BCAA granules: A pilot study.
    Fukui A; Kawabe N; Hashimoto S; Murao M; Nakano T; Shimazaki H; Kan T; Nakaoka K; Ohki M; Takagawa Y; Kamei H; Yoshioka K
    Turk J Gastroenterol; 2015 Jul; 26(4):328-35. PubMed ID: 26039003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High serum alanine aminotransferase levels for the first three successive years can predict very high incidence of hepatocellular carcinoma in patients with Child Stage A HCV-associated liver cirrhosis.
    Miyakawa K; Tarao K; Ohshige K; Morinaga S; Ohkawa S; Okamoto N; Shibuya A; Adachi S; Miura Y; Fujiyama S; Miyase S; Tomita K
    Scand J Gastroenterol; 2009; 44(11):1340-8. PubMed ID: 19891585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status.
    Kawamura E; Habu D; Morikawa H; Enomoto M; Kawabe J; Tamori A; Sakaguchi H; Saeki S; Kawada N; Shiomi S
    Liver Transpl; 2009 Jul; 15(7):790-7. PubMed ID: 19562716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis.
    Takagi H; Kakizaki S; Sohara N; Sato K; Tsukioka G; Tago Y; Konaka K; Kabeya K; Kaneko M; Takayama H; Hashimoto Y; Yamada T; Takahashi H; Shimojo H; Nagamine T; Mori M
    Int J Vitam Nutr Res; 2003 Nov; 73(6):411-5. PubMed ID: 14743544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis.
    Nishiguchi S; Habu D
    Hepatol Res; 2004 Dec; 30S():36-41. PubMed ID: 15607137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.
    Takegoshi K; Honda M; Okada H; Takabatake R; Matsuzawa-Nagata N; Campbell JS; Nishikawa M; Shimakami T; Shirasaki T; Sakai Y; Yamashita T; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Mar; 8(11):18191-18205. PubMed ID: 28212548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients.
    Khan KN; Yatsuhashi H
    Alcohol Alcohol; 2000; 35(3):286-95. PubMed ID: 10869250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection.
    Yu L; Paski SC; Dodge J; Bambha K; Biggins SW; Ioannou GN
    PLoS One; 2023; 18(4):e0284739. PubMed ID: 37098004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late evening snacks with branched-chain amino acids improve the Fischer ratio with patients liver cirrhosis at fasting in the next morning.
    Maki H; Yamanaka-Okumura H; Katayama T; Ozawa Y; Hosoda A; Kurata N; Amemiya F
    Clin Nutr ESPEN; 2019 Apr; 30():138-144. PubMed ID: 30904214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late-Evening Snack with Branched-Chain Amino Acid-Enriched Nutrients Does Not Always Inhibit Overt Diabetes in Patients with Cirrhosis: A Pilot Study.
    Nakanishi K; Namisaki T; Mashitani T; Kaji K; Ozaki K; Saikawa S; Sato S; Inoue T; Sawada Y; Kitagawa K; Takaya H; Shimozato N; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    Nutrients; 2019 Sep; 11(9):. PubMed ID: 31500257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Branched-chain amino acids supplementation improves liver frailty index in frail compensated cirrhotic patients: a randomized controlled trial.
    Siramolpiwat S; Limthanetkul N; Pornthisarn B; Vilaichone RK; Chonprasertsuk S; Bhanthumkomol P; Nunanan P; Issariyakulkarn N
    BMC Gastroenterol; 2023 May; 23(1):154. PubMed ID: 37189033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.